Phase IV, open-label, multicentre trial of afatinib in patients (pts) aged ≥70 yrs with NSCLC harbouring common (Del19/L858R) EGFR mutations: Preliminary results
Year: 2018
Type: article
Abstract: Background: The irreversible ErbB family blocker, afatinib, is approved for first-line treatment of metastatic NSCLC harbouring non-resistant EGFR mutations. While afatinib has demonstrated a predictable and manageable safety profile in pts with EGFR mutation-positive (EGFRm+) NSCLC, elderly pts are often under-represented in clinical trials. Here, we summarise the current status of, and preliminary data from, an ongoing Phase IV trial of afatinib in elderly pts with Del19/L858R EGFRm+ NSCLC (NCT02514174).
Source: Annals of Oncology
Institutions: City Of Hope National Medical Center, City of Hope, Lankenau Medical Center, Albert Einstein College of Medicine, Montefiore Medical Center, Montefiore Einstein Comprehensive Cancer Center, University of Miami, Sylvester Comprehensive Cancer Center, Baystate Medical Center, Baystate Health, Mayo Clinic Hospital, University of Chicago Medical Center, Boehringer Ingelheim (United States), Syneos Health (United States)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2896425786